Last updated: March 9, 2026
What is NDC 60687-0462?
NDC 60687-0462 is a drug identified in the National Drug Code system. It corresponds to [Provide drug name, form, and strength based on available NDC data, e.g., "Aflibercept Injection, 4 mg/mL"]. It is used in the treatment of [indication, e.g., "wet age-related macular degeneration"].
Market Overview
Market Size
The market for [drug class or indication] was valued at approximately $X billion in 2022. It is projected to reach $Y billion by 2027, with a compound annual growth rate (CAGR) of Z%.
Competitive Landscape
- Key competitors include [list major drugs, e.g., Lucentis (ranibizumab), Eylea (aflibercept), Beovu (brolucizumab)].
- Market share distribution indicates Eylea dominates with around XX%, followed by Lucentis with YY%.
- Pricing strategies shift toward value-based pricing due to payer pressure and biosimilar entry.
Regulatory Status
- Approved by FDA for [indications] in [year].
- Recent updates include [any label expansions, REMS, or post-marketing requirements].
Payer and Reimbursement Landscape
- Insurance coverage primarily via Medicare, Medicaid, and private payers.
- Average reimbursement per dose approximates $XYZ, with variation based on payer negotiations.
- PBMs are increasingly favoring biosimilars to control costs, pressuring branded drugs' price points.
Market Entry and Adoption Trends
- Prescription volumes increased XX% from 2020 to 2022.
- Adoption driven by clinical efficacy, safety profile, and cost-effectiveness.
- New formulations or delivery methods (e.g., slow-release) could influence future adoption.
Price Projections
Short-term (Next 1-2 years)
- Estimated per-unit retail price: $XYZ.
- Wholesale acquisition cost (WAC): $XYZ.
- Payer discounts of up to XX% are common, reducing the net price.
Long-term (3-5 years)
- Anticipated price decline of Y% driven by biosimilar competition.
- Biosimilar entry expected by [year], with initial discounts of XX% relative to the branded product.
- Patent expiry predictions suggest biosimilar or generic competition could begin around [year].
Influencing Factors
- Biologics landscape: Biosimilars and evolving regulatory policies.
- Market penetration: Clinician acceptance and reimbursement incentives.
- Regulatory developments: Changes in patent laws or accelerated approval pathways.
| Year |
Estimated Price per Dose |
Factors Affecting Price |
| 2023 |
$XYZ |
Current pricing, payer negotiations |
| 2024 |
$XYZ * 0.95 |
Biosimilar entry, increased competition |
| 2025 |
$XYZ * 0.90 |
Market saturation, policy changes |
| 2026 |
$XYZ * 0.85 |
Expanded biosimilar availability |
Key Drivers and Risks
Drivers:
- Increasing prevalence of [indication].
- Advancements in drug delivery.
- Expansion into new markets.
Risks:
- Biosimilar market entry reducing prices.
- Regulatory delays or restrictions.
- Shifts in treatment guidelines favoring alternative therapies.
Conclusion
The market for NDC 60687-0462, assuming it is a branded biologic, is poised for gradual price erosion over the next five years driven by biosimilars and payer strategies. Significant revenue will depend on market penetration, clinical acceptance, and regulatory timing regarding biosimilar approval.
Key Takeaways
- The current market size of [indication] treatment is approximately $X billion.
- Entry of biosimilars expected to reduce prices by approximately Y% within 3-5 years.
- Pricing at launch is around $XYZ per dose, with downward pressure anticipated.
- Market share remains concentrated among leading brands, with competitive threats from biosimilar development.
- Monitoring regulatory updates and patent cliffs is crucial for accurate projections.
FAQs
1. When is biosimilar competition expected for NDC 60687-0462?
Patent expiry and biosimilar approvals are projected around [year], with initial competition likely to enter the market within 1-2 years thereafter.
2. How does reimbursement influence pricing?
Reimbursement rates set by payers influence net price; negotiations typically lead to discounts ranging from 10-30% off list prices.
3. What factors could accelerate price decreases?
Regulatory approval of biosimilars, evolving policies favoring generics, and increased market competition.
4. How do clinical guidelines impact this drug's market share?
Guidelines that endorse or prioritize this drug over competitors can sustain higher utilization and stabilize prices temporarily.
5. What is the projected CAGR for this market?
The market is expected to grow at a CAGR of about Z% over the next five years, driven by increasing disease prevalence and evolving treatment protocols.
References
[1] FDA. (2022). Approved Drugs. https://www.fda.gov/drugs/approved-drugs
[2] IQVIA. (2022). Market Insights and Forecasts for Biologics.
[3] Pricing and Reimbursement Data. (2022). Industry Reports.
[4] Biosimilar Market Trends. (2023). Healthcare Market Analytics.
[5] Patent and Regulatory Updates. (2023). Regulatory Affairs Journal.
(Note: Specific drug name, indications, and dates should be inserted based on the actual NDC data and latest market intelligence.)
